DPY30 was identified as a promoter of cancer cell proliferation and tumor survival. Targeting this protein may enhance the ...
Researchers at The University of Texas MD Anderson Cancer Center have identified an epigenetic target for replication stress, ...
Detailed price information for Maia Biotechnology Inc (MAIA-A) from The Globe and Mail including charting and trades.
An octopus-shaped nanomachine hijacks tumor ATP leakage to power a self-amplifying cycle of membrane damage, drug delivery, and metabolic collapse in cancer cells.
Acute myeloid leukemia (AML) remains one of the most difficult blood cancers to treat. Although drug combinations are often ...
Together, all three DENALI Part 2 cohorts are designed to support a potential accelerated approval pathway in the Cyclin E1 biomarker selected patient population, subject to regulatory review.
Strong participation in recent $33 million common stock offering highlights investor confidence in late-stage clinical momentum and commercial potential Statistical assessments point to high probabili ...
Cancer treatment has long been haunted by the same problem: how do you strike dangerous cells without hitting healthy ones ...
Potential breakthrough therapeutic targets $50B+ global immunotherapy market1 CHICAGO, March 31, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results